Phase II trials of fosquidone, (GR63178A), in colorectal, renal and non-small cell lung cancer. CRC Phase II Clinical Trials Committee.
A total of 61 eligible patients with metastatic cancer have been treated in a series of Phase II trials of the novel pentacyclic pyrroloquinone, fosquidone. Tumour types were colorectal (23), renal (21), and non small cell lung (17). No patient had received prior chemotherapy. The drug was given intravenously as a 20 min infusion at the dose of 120 mg-2 on days 1 to 5 every 3 weeks. Treatment was well tolerated; the only significant side effects being mild nausea and generalised musculo-skeletal pains. Response was assessed after two cycles of therapy. No patient achieved an objective partial response. A total of nine patients demonstrated stable disease for a median duration of 11 weeks. Using this schedule of administration, fosquidone has no significant antitumour activity in this group of tumours.
Kaye
S B
SB
Beatson Oncology Centre, Western Infirmary, Glasgow, UK.
Brampton
M
M
Harper
P
P
Smyth
J
J
Kerr
D J
DJ
Gore
M
M
Green
J A
JA
Gilby
E
E
Crawford
S M
SM
Rustin
G J
GJ
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009943:Organophosphorus Compounds
D000970:Antineoplastic Agents; D007546:Isoquinolines; D009943:Organophosphorus Compounds; C072687:fosquidone